

**First Quarter Financial Statements Announcement For The Period Ended 30 June 2015**  
**(In accordance with International Financial Reporting Standards)**

**PART I - INFORMATION REQUIRED FOR ANNOUNCEMENTS OF QUARTERLY (Q1, Q2 & Q3), HALF-YEAR AND FULL YEAR RESULTS**

**1(a) An income statement (for the group) together with a comparative statement for the corresponding period of the immediately preceding financial year.**

**Consolidated Income Statement for the first quarter ended 30 June 2015**

	Note	The Group		
		1st Quarter Ended		
		30-Jun-15	30-Jun-14	Change
		US\$'000	US\$'000	%
<b>Revenue</b>				
Product revenue	A	60,532	70,469	(14)
Licensing and royalties revenue		6,495	9,742	(33)
<b>Total revenue</b>		<b>67,027</b>	<b>80,211</b>	(16)
<b>Total cost of sales</b>		(15,998)	(20,480)	(22)
<b>Gross profit</b>		<b>51,029</b>	<b>59,731</b>	(15)
<b>Operating expenses</b>				
Sales and marketing expenses	B	(20,290)	(26,925)	(25)
General and administrative expenses	C	(7,835)	(10,653)	(26)
Research and development expenses	D	(4,622)	(7,049)	(34)
		(32,747)	(44,627)	(27)
<b>Profit from operations</b>	E	<b>18,282</b>	<b>15,104</b>	21
Other income/(expenses), net	F	(1,082)	(261)	315
Financial income	G	2,047	1,731	18
Financial expenses	H	(3,351)	(3,413)	(2)
<b>Profit before exceptional and non-operating items</b>		<b>15,896</b>	<b>13,161</b>	21
Amortisation of customer lists and patents		(4,633)	(4,635)	(0)
Exceptional items				
- restructuring of operations		(754)	-	NM
<b>Profit before tax</b>		<b>10,509</b>	<b>8,526</b>	23
Income tax	I	(1,046)	1,345	NM
<b>Net profit for the period</b>		<b>9,463</b>	<b>9,871</b>	(4)
<b>Attributable to:</b>				
Equity holders of the Company		9,463	9,871	
<b>Earnings per share (US cent)</b>	(see footnotes)			
<b>Before exceptional items</b>				
Basic		0.61	0.58	
Diluted		0.61	0.58	
<b>After exceptional items</b>				
Basic		0.56	0.58	
Diluted		0.56	0.58	

NM - Not meaningful

## Consolidated Statement of Comprehensive Income

The Group		
1st Quarter Ended		
30-Jun-15	30-Jun-14	Change
US\$'000	US\$'000	%
9,463	9,871	(4)
4,104	21,854	(81)
<b>13,567</b>	<b>31,725</b>	

### Net profit for the period

### Other comprehensive income:

Exchange differences on translation of financial statements of foreign subsidiaries

### Total comprehensive income

### Attributable to:

Equity holders of the Company

13,567	31,725
1,681,585	1,697,429
1,687,084	1,715,136

### Footnotes

<sup>1</sup> Weighted average ordinary shares issued ('000)

<sup>2</sup> Weighted average ordinary shares and equivalents outstanding ('000)

Basic earnings per share is calculated by dividing the profit for the period by the weighted average number of shares in issue during the period excluding ordinary shares purchased by the Company and held as treasury shares.

Diluted earnings per share is calculated by dividing the profit for the period by the weighted average number of shares in issue during the period excluding ordinary shares purchased by the Company and held as treasury shares adjusted for the effects of dilutive options.

## Notes to the Income Statements

### A Product revenue

Critical care products  
Interventional cardiology products  
Cardiac diagnostic

The Group	
1st Quarter Ended	
30-Jun-15	30-Jun-14
US\$'000	US\$'000
3,756	4,377
53,504	61,695
3,272	4,397
<b>60,532</b>	<b>70,469</b>

- B Sales and marketing expenses decreased 25% to US\$20.3 million for the quarter ended 30 June 2015 compared to US\$26.9 million for the quarter ended 30 June 2014 mainly due to reduction in payroll related expenses, marketing and promotion expenses, warehousing & logistics expenses and doubtful debt expenses.
- C General and administrative expenses decreased 26% to US\$7.8 million from US\$10.7 million in the corresponding quarter of last year mainly due to decreased payroll related expenses, share-based expenses, consulting and professional fees.
- D Research and development expenses decreased 34% to US\$4.6 million compared to US\$7.0 million in the quarter ended 30 June 2014, mainly due to lower payroll related expenses and clinical and animal trials expenses.
- E Profit from operations is determined after (charging)/crediting the following:

Depreciation of property, plant and equipment  
Amortisation of intangible assets (excluding customer lists and patents)  
Realisation of deferred revenue  
Write-back of/(allowance for) doubtful trade debts, net  
Write-back of doubtful non-trade debts, net  
Inventories write-down, net  
Provision for warranty, net  
Reversal/(provision) for sales return  
Intangible assets written off  
Property, plant and equipment written off  
Inventories written off  
(Loss)/gain on disposal of property, plant and equipment  
Foreign exchange losses

The Group	
1st Quarter Ended	
30-Jun-15	30-Jun-14
US\$'000	US\$'000
(1,417)	(1,717)
(481)	(260)
2,025	2,598
1,419	(690)
2	3
(314)	(2,470)
(2)	(21)
55	(255)
58	-
(15)	(55)
(979)	(195)
(5)	1
(1,024)	(249)

F Other income/(expenses), net

	<u>The Group</u>	
	<u>1st Quarter Ended</u>	
	<u>30-Jun-15</u>	<u>30-Jun-14</u>
	US\$'000	US\$'000
(Loss)/gain on disposal of property, plant and equipment, net	(5)	1
Foreign exchange (loss), net	(1,024)	(249)
Other miscellaneous expenses, net	(53)	(13)
	<u>(1,082)</u>	<u>(261)</u>

Other operating expenses for the quarter was mainly the exchange loss from the depreciation of SGD and EUR against USD during the period.

G Financial income

	<u>1st Quarter Ended</u>	
	<u>30-Jun-15</u>	<u>30-Jun-14</u>
	US\$'000	US\$'000
Interest income		
- bank balances	221	369
- fixed deposits	1,806	1,342
- others	20	20
	<u>2,047</u>	<u>1,731</u>

H Financial expenses

	<u>1st Quarter Ended</u>	
	<u>30-Jun-15</u>	<u>30-Jun-14</u>
	US\$'000	US\$'000
Interest expense		
- long term loan	(407)	(195)
- notes payable	(2,937)	(3,196)
- others	(7)	(22)
	<u>(3,351)</u>	<u>(3,413)</u>

I Income tax

Income tax for the current quarter ended 30 June 2015 includes mainly corporate income tax expenses.

**1(b)(i) A balance sheet (for the issuer and group), together with a comparative statement as at the end of the immediately preceding financial year.**

**Consolidated Balance Sheets as at 30 June 2015**

Note	The Group		The Company	
	30-Jun-15	31-Mar-15	30-Jun-15	31-Mar-15
	US\$'000	US\$'000	US\$'000	US\$'000
<b>Non-Current Assets</b>				
Property, plant and equipment	86,133	86,289	-	-
Investment in subsidiaries	-	-	584,716	584,716
Other investments	29,344	28,836	29,344	28,836
Intangible assets	132,826	134,875	13,435	12,199
Deposits pledged for bank loans	1,111	1,092	-	-
Goodwill	440,786	439,576	52,579	52,579
Deferred tax assets	260	258	-	-
Long term loan to a third party	1,500	1,500	-	-
Long term loans to subsidiaries	-	-	56,828	56,616
<b>Current Assets</b>				
Inventories	45,539	44,474	-	-
Trade receivables	70,459	73,121	-	-
Other receivables	2,408	4,059	-	-
Deposits and prepayments	17,478	15,058	2,137	523
Due from subsidiaries (non-trade)	-	-	15,487	13,303
Due from subsidiaries (trade)	-	-	11,450	7,042
Short term loan to a third party	500	500	-	-
Deposits pledged for bank loans	45,993	47,793	-	-
Cash and cash equivalents	536,477	518,253	293,241	298,656
	718,854	703,258	322,315	319,524
Less:				
<b>Current Liabilities</b>				
Trade payables	7,435	6,605	-	-
Other payables	20,112	18,939	762	768
Accruals	20,814	26,702	1,243	2,291
Provisions	2,727	2,747	-	-
Due to subsidiaries (non-trade)	-	-	20,241	18,413
Provision for income tax	7,237	6,845	389	23
Deferred revenue, current portion	2,197	1,678	-	-
Finance lease liabilities, current portion	19	19	-	-
Borrowings	41,476	41,433	39,000	41,046
Contingent consideration	2,410	2,410	2,410	2,410
	104,427	107,378	64,045	64,951
<b>Net Current Assets</b>	614,427	595,880	258,270	254,573
Less:				
<b>Non-Current Liabilities</b>				
Deferred tax liabilities	14,725	15,220	-	-
Deferred revenue, non-current portion	974	1,561	-	-
Finance lease liabilities, non-current portion	56	60	-	-
Borrowings	258,306	254,260	220,753	211,819
Other payables - non current	70	78	70	78
Pension funds	2,730	2,701	-	-
	276,861	273,880	220,823	211,897
	1,029,526	1,014,426	774,349	777,622
<b>Capital and Reserves</b>				
Share capital	117	117	117	117
Share premium	746,857	746,042	746,857	746,042
Treasury shares	(54,692)	(54,692)	(54,692)	(54,692)
Translation reserves	49,731	45,627	-	-
Other reserves	20,243	19,525	19,197	18,479
Accumulated profits	267,270	257,807	62,870	67,676
	1,029,526	1,014,426	774,349	777,622
<b>Net assets values</b>				
Net assets per share (US cent)	61.13	60.36	45.98	46.27
Footnote				
Number of shares in issue at end of period ('000)	1,684,050	1,680,706	1,684,050	1,680,706

Net assets per share is calculated by dividing the net assets by the number of shares in issue as at the balance sheet date.

## Notes to the Balance Sheets

A	<u>Other investments</u>	<u>The Group</u>		<u>The Company</u>	
		<u>30-Jun-15</u>	<u>31-Mar-15</u>	<u>30-Jun-15</u>	<u>31-Mar-15</u>
		US\$'000	US\$'000	US\$'000	US\$'000
	Available-for-sale				
	Unquoted convertible bonds, at cost	3,000	3,000	3,000	3,000
	Unquoted shares, at cost	15,344	14,836	15,344	14,836
		<u>18,344</u>	<u>17,836</u>	<u>18,344</u>	<u>17,836</u>
	Held for trading				
	Unquoted equity warrants, at cost	11,000	11,000	11,000	11,000
		<u>29,344</u>	<u>28,836</u>	<u>29,344</u>	<u>28,836</u>
B	<u>Inventories</u>	<u>The Group</u>		<u>The Company</u>	
		<u>30-Jun-15</u>	<u>31-Mar-15</u>	<u>30-Jun-15</u>	<u>31-Mar-15</u>
		US\$'000	US\$'000	US\$'000	US\$'000
	Finished goods	23,436	22,636		
	Work-in-progress	5,050	5,225		
	Sub-assemblies	5,574	4,192		
	Raw materials	11,182	11,507		
	Goods-in-transit	297	914		
	Total inventories at lower of cost and net realisable value	<u>45,539</u>	<u>44,474</u>		
C	<u>Trade receivables</u>	<u>The Group</u>		<u>The Company</u>	
		<u>30-Jun-15</u>	<u>31-Mar-15</u>	<u>30-Jun-15</u>	<u>31-Mar-15</u>
		US\$'000	US\$'000	US\$'000	US\$'000
	Trade receivables	75,117	79,075		
	Less: allowance for doubtful trade debts	(4,658)	(5,954)		
		<u>70,459</u>	<u>73,121</u>		
	Movements in allowance for doubtful trade debts during the period were as follows:				
	At beginning of year	5,954	8,514		
	Reversal for the year	(1,419)	(449)		
	Written off against allowance	-	(555)		
	Translation differences	123	(1,556)		
	At end of year	<u>4,658</u>	<u>5,954</u>		
D	<u>Deposits and prepayments</u>	<u>The Group</u>		<u>The Company</u>	
		<u>30-Jun-15</u>	<u>31-Mar-15</u>	<u>30-Jun-15</u>	<u>31-Mar-15</u>
		US\$'000	US\$'000	US\$'000	US\$'000
	Deposits	491	881	-	162
	Prepayments	16,987	14,177	2,137	361
		<u>17,478</u>	<u>15,058</u>	<u>2,137</u>	<u>523</u>
E	<u>Other payables</u>	<u>The Group</u>		<u>The Company</u>	
		<u>30-Jun-15</u>	<u>31-Mar-15</u>	<u>30-Jun-15</u>	<u>31-Mar-15</u>
		US\$'000	US\$'000	US\$'000	US\$'000
	Accrued operating expenses	13,408	15,034		
	Accrued payroll expense	7,406	11,402		
	Accrued purchases	-	266		
		<u>20,814</u>	<u>26,702</u>		
G	<u>Deferred revenue</u>	<u>The Group</u>		<u>The Company</u>	
		<u>30-Jun-15</u>	<u>31-Mar-15</u>	<u>30-Jun-15</u>	<u>31-Mar-15</u>
		US\$'000	US\$'000	US\$'000	US\$'000
	Cross-border loans	39,000	39,000		
	Medium terms notes	220,710	216,708		
	Construction loan	40,072	39,985		
		<u>299,782</u>	<u>295,693</u>		

**1(b)(ii) Aggregate amount of group's borrowings and debt securities.**

**Amount repayable in one year or less, or on demand**

As at 30-Jun-15	
Secured	Unsecured
US\$'000	US\$'000
41,495	0

As at 31-Mar-15	
Secured	Unsecured
US\$'000	US\$'000
41,452	0

**Amount repayable after one year**

As at 30-Jun-15	
Secured	Unsecured
US\$'000	US\$'000
258,362	0

As at 31-Mar-15	
Secured	Unsecured
US\$'000	US\$'000
254,320	0

**Details of any collateral**

- (i) The banking facilities of a subsidiary, amounting to approximately US\$5.9 million, granted by two of the banks are secured by corporate guarantees from the Company.
- (ii) The partially drawn mortgage loan facilities of a subsidiary, amounting to approximately US\$44.4 million, is secured by corporate guarantees from the Company and fixed deposit of S\$1.5 million.
- (iii) The finance lease obligations are secured on office equipment with net book values of approximately US\$67,000 (31 March 2015 : US\$ 71,000).
- (iv) The Company has been granted US\$39 million credit facilities for the purposes of facilitating cross-border cash management which are secured by pledged deposits of a subsidiary.
- (v) Fixed rate notes of S\$300 million (approximate US\$222 million) issued by a subsidiary under the Group's medium term note programme are guaranteed by the Company.

**1(c) A cash flow statement (for the group), together with a comparative statement for the corresponding period of the immediately preceding financial year.**

**Consolidated Statements of Cash Flows for the first quarter ended 30 June 2015**

**Cash Flows from Operating Activities**

Profit before tax

Adjustments:

Amortisation of intangible assets

Realisation of deferred revenue

Impairment of property, plant and equipment

Impairment of intangible assets

Depreciation of property, plant and equipment

Property, plant and equipment written off

Loss/(gain) on disposal of property, plant and equipment

Inventories written off

(Write-back of)/allowance for doubtful trade debts, net

Write-back of doubtful non-trade debts

Provision for warranty, net

(Reversal)/provision for sales return

Intangible assets written off

Share-based expenses

Inventories write-down, net

Interest expenses

Interest income

Translation differences

**Operating cash flows before working capital changes**

(Increase)/Decrease in:

Inventories

Trade and other receivables

Increase/(Decrease) in:

Trade and other payables

Deferred revenue

Pension funds

**Cash generated from operations**

Income tax paid, net

Interest income received

Interest expenses paid

**Net cash generated from operating activities**

**Cash Flows from Investing Activities**

Purchase of other investments

Purchase of property, plant and equipment

Purchase of intangible assets

Proceeds from sale of property, plant and equipment

**Net cash used in investing activities**

**Cash Flows from Financing Activities**

Repayment of finance leases

(Payment)/proceeds from long-term bank borrowings

Proceeds from issuance of new shares

**Net cash (used in)/generated from financing activities**

**Net increase in cash and cash equivalents**

**Cash and cash equivalents at beginning of the period**

**Net effect of exchange rate changes on cash and cash equivalents**

**Cash and cash equivalents at end of the period (Note A)**

<b>The Group</b>	
<b>1st Quarter Ended</b>	
<b>30-Jun-15</b>	<b>30-Jun-14</b>
US\$'000	US\$'000
10,509	8,526
5,114	4,895
(2,025)	(2,598)
58	(66)
108	-
1,417	1,717
15	55
5	(1)
979	195
(1,419)	690
(2)	(3)
2	21
(55)	255
(58)	-
1,001	1,783
314	2,470
3,351	3,413
(2,047)	(1,731)
1,598	2,504
18,865	22,125
(2,446)	(3,697)
5,142	(6,763)
(6,248)	2,555
1,926	2,373
-	78
17,239	16,671
(1,585)	(1,630)
2,047	1,731
(414)	(217)
17,287	16,555
(508)	-
(463)	(15,547)
(2,624)	(1,415)
138	1
(3,457)	(16,961)
(3)	-
(613)	11,077
532	597
(84)	11,674
13,746	11,268
518,253	511,788
4,478	8,197
536,477	531,253

**Note to the consolidated statements of cash flows:**

**A. Cash and cash equivalents**

Cash and cash equivalents consist of cash and bank balances, fixed deposits and money markets deposits. Cash and cash equivalents included in the consolidated statements of cash flows comprise the following balance sheet amounts:

	<u>The Group</u>	
	<u>1st Quarter Ended</u>	
	<u>30-Jun-15</u>	<u>30-Jun-14</u>
	US\$'000	US\$'000
Cash and bank balances	231,007	360,661
Fixed deposits	273,317	157,067
Money markets deposits	32,153	13,525
	<u>536,477</u>	<u>531,253</u>



1(d) (i) A statement (for the issuer and group) showing either (i) all changes in equity or (ii) changes in equity other than those arising from capitalisation issues and distributions to shareholders, together with a comparative statement for the corresponding period of the immediately preceding financial year.

**Statement of changes in equity for the first quarter ended 30 June 2015**

	Attributable to equity holders of the Company						Total Equity
	Share Capital	Share Premium	Treasury Shares	Translation Reserves	Other Reserves	Accumulated Profit	
	US\$'000	US\$'000	US\$'000	US\$'000	US\$'000	US\$'000	US\$'000
<b>The Group</b>							
<b>At 1 April 2015</b>	117	746,042	(54,692)	45,627	19,525	257,807	1,014,426
Profit net of tax	-	-	-	-	-	9,463	9,463
Exchange differences on translation of financial statements of foreign subsidiaries	-	-	-	4,104	-	-	4,104
<b>Total comprehensive income</b>	-	-	-	<b>4,104</b>	-	<b>9,463</b>	<b>13,567</b>
Contributions by and distributions to owners							
Issue of ordinary shares pursuant to the exercise of share options	-	*	532	-	-	-	532
Transfer of reserve pursuant to the exercise of share options	-	283	-	-	(283)	-	-
Share-based expenses	-	-	-	-	1,001	-	1,001
<b>Total contributions by and distributions to owners</b>	-	<b>815</b>	-	-	<b>718</b>	-	<b>1,533</b>
<b>At 30 June 2015</b>	<b>117</b>	<b>746,857</b>	<b>(54,692)</b>	<b>49,731</b>	<b>20,243</b>	<b>267,270</b>	<b>1,029,526</b>
<b>At 1 April 2014</b>	117	740,034	(48,792)	50,839	27,327	483,520	1,253,045
Profit net of tax	-	-	-	-	-	9,871	9,871
Exchange differences on translation of financial statements of foreign subsidiaries	-	-	-	21,854	-	-	21,854
<b>Total comprehensive income</b>	-	-	-	<b>21,854</b>	-	<b>9,871</b>	<b>31,725</b>
Contributions by and distributions to owners							
Issue of ordinary shares pursuant to the exercise of share options	-	*	598	-	-	-	598
Transfer of reserve pursuant to the exercise of share options	-	299	-	-	(299)	-	-
Share-based expenses	-	-	-	-	1,783	-	1,783
<b>Total contributions by and distributions to owners</b>	-	<b>897</b>	-	-	<b>1,484</b>	-	<b>2,381</b>
<b>At 30 June 2014</b>	<b>117</b>	<b>740,931</b>	<b>(48,792)</b>	<b>72,693</b>	<b>28,811</b>	<b>493,391</b>	<b>1,287,151</b>

Footnote

\* Amounts are less than US\$1,000.

**Statement of changes in equity for the first quarter ended 30 June 2015**

	Attributable to equity holders of the Company						
	Share Capital	Share Premium	Treasury Shares	Translation Reserves	Other Reserves	Accumulated Profit	Total Equity
	US\$'000	US\$'000	US\$'000	US\$'000	US\$'000	US\$'000	US\$'000
<b><u>The Company</u></b>							
<b>At 1 April 2015</b>	117	746,042	(54,692)	-	18,479	67,676	777,622
Profit net of tax representing total comprehensive income	-	-	-	-	-	(4,806)	(4,806)
Contributions by and distributions to owners							
Issue of ordinary shares pursuant to the exercise of share options	-	*	532	-	-	-	532
Transfer of reserve pursuant to the exercise of share options	-		283	-	(283)	-	-
Share-based expenses	-	-	-	-	1,001	-	1,001
<b>Total contributions by and distribution to owners</b>	-	<b>815</b>	-	-	<b>718</b>	-	<b>1,533</b>
<b>At 30 June 2015</b>	<b>117</b>	<b>746,857</b>	<b>(54,692)</b>	<b>-</b>	<b>19,197</b>	<b>62,870</b>	<b>774,349</b>
<b>At 1 April 2014</b>	117	740,034	(48,792)	-	26,822	55,474	773,655
Profit net of tax representing total comprehensive income	-	-	-	-	-	(1,424)	(1,424)
Contributions by and distributions to owners							
Issue of ordinary shares pursuant to the exercise of share options	-	*	598	-	-	-	598
Transfer of reserve pursuant to the exercise of share options	-		299	-	(299)	-	-
Share-based expenses	-	-	-	-	1,783	-	1,783
<b>Total contributions by and distribution to owners</b>	-	<b>897</b>	-	-	<b>1,484</b>	-	<b>2,381</b>
<b>At 30 June 2014</b>	<b>117</b>	<b>740,931</b>	<b>(48,792)</b>	<b>-</b>	<b>28,306</b>	<b>54,050</b>	<b>774,612</b>

Footnote

\* Amounts are less than US\$1,000.

**Note to the Statement of Changes in Equity**

Other reserves consist of the following:

	The Group		The Company	
	30-Jun-15	30-Jun-14	30-Jun-15	30-Jun-14
	US\$'000	US\$'000	US\$'000	US\$'000
Employee share options reserve	14,018	23,127	14,018	23,127
Statutory reserve	1,046	505	-	-
Capital reserves	1,561	1,561	1,561	1,561
Equity component of convertible notes	3,618	3,618	3,618	3,618
	<b>20,243</b>	<b>28,811</b>	<b>19,197</b>	<b>28,306</b>

- 1(d)(ii) Details of any changes in the company's share capital arising from rights issue, bonus issue, share buy-backs, exercise of share options or warrants, conversion of other issues of equity securities, issue of shares for cash or as consideration for acquisition or for any other purpose since the end of the previous period reported on. State also the number of shares that may be issued on conversion of all the outstanding convertibles as at the end of the current financial period reported on and as at the end of the corresponding period of the immediately preceding financial year.**

**A. Changes in share capital**

For the quarter ended 30 June 2015, the Company issued 1,067,038 and 2,276,666 new ordinary shares of par value 1/150 US cent each pursuant to the exercise of options and Performance Share Plan respectively. The issued ordinary shares (excluding treasury shares) increased from 1,680,706,011 shares as at 31 March 2015 to 1,684,049,715 shares of par value 1/150 US cent each at the end of the quarter ended 30 June 2015.

**B. Stock options and performance shares outstanding**

As at 30 June 2015, options in respect of a total of 41,244,397 (31 March 2015: 31,665,213) ordinary shares of par value 1/150 US cent each and 5,723,334 (31 March 2015: 8,000,000) performance shares pursuant to Biosensors Performance Share Plan were outstanding.

- 1(d)(iii) To show the total number of issued shares excluding treasury shares as at the end of the current financial period and as at the end of the immediately preceding year.**

	As at 30-Jun-15 '000	As at 31-Mar-15 '000
Total number of issued shares	1,762,712	1,759,368
Less number of shares held as treasury shares	(78,662)	(78,662)
Number of shares in issue excluding treasury shares of the Issuer at end of period	<u>1,684,050</u>	<u>1,680,706</u>

- 1(d)(iv) A statement showing all sales, transfers, disposal, cancellation and/or use of treasury shares as at the end of the current financial period reported on.**

	Number of Treasury Shares '000
Balance as at 1 April 2015 and 30 June 2015	<u>78,662</u>

- 2. Whether the figures have been audited or reviewed and in accordance with which auditing standard or practice.**

The figures have not been audited nor reviewed by the auditors.

- 3. Where the figures have been audited or reviewed, the auditors' report (including any qualifications or emphasis of matter).**

Not applicable.

- 4. Whether the same accounting policies and methods of computation as in the issuer's most recently audited annual financial statements have been applied.**

The Group has applied the same accounting policies and methods of computation in the financial statements for the current reporting period as in the audited financial statements for the financial year ended 31 March 2015 except for the adoption of new/revised IFRSs and IFRIC Interpretations that are effective for annual periods beginning on or after 1 April 2015.

- 5. If there are any changes in the accounting policies and methods of computation, including any required by an accounting standard, what has changed, as well as the reasons for, and the effect of, the change.**

The Group adopted the new/revised IFRSs and IFRIC Interpretations that are effective for annual periods beginning on or after 1 April 2015. Changes to the Group's accounting policies have been made as required, in accordance with the transitional provisions in the respective IFRSs and IFRIC Interpretations.

The following are the new or amended IFRSs that are relevant to the Group:	Effective date
Amendments to IAS 19 – Defined Benefit Plans: Employee Contributions	1 July 2014
IFRS 2 – Share-based Payments	1 July 2014
IFRS 3 – Business Combinations	1 July 2014
IFRS 8 – Operating Segments	1 July 2014
IAS 16 – Property, Plant and Equipment and IAS 38 – Intangible Assets	1 July 2014
IAS 24 – Related Party Disclosures	1 July 2014
IFRS 13 – Fair Value Measurement	1 July 2014

The adoption of the above IFRSs and IFRIC interpretations do not have any significant impact on the financial statements of the Group.

**6. Earnings per ordinary share of the group for the current financial period reported on and the corresponding period of the immediately preceding financial year, after deducting any provision for preference dividends.**

		<u>1st Quarter Ended</u>	
		<u>30-Jun-15</u>	<u>30-Jun-14</u>
		US cent	US cent
Earnings per ordinary share of the Group:-			
(a) Based on the weighted average number of ordinary shares; and	1		
- Before exceptional items		0.61	0.58
- After exceptional items		0.56	0.58
(b) On a fully diluted basis	2		
- Before exceptional items		0.61	0.58
- After exceptional items		0.56	0.58
<sup>1</sup> Weighted average ordinary shares issued ('000)		1,681,585	1,697,429
<sup>2</sup> Weighted average ordinary shares and equivalents outstanding ('000)		1,687,084	1,715,136

Basic earnings per share is calculated by dividing the profit for the period by the weighted average number of shares in issue during the period excluding ordinary shares purchased by the Company and held as treasury shares.

Diluted earnings per share is calculated by dividing the profit for the period by the weighted average number of shares in issue during the period, excluding ordinary shares purchased by the Company and held as treasury shares, adjusted for the effects of dilutive options.

**7. Net asset value (for the issuer and group) per ordinary share based on issued share capital of the issuer at the end of the:-**

**(a) current financial period reported on; and  
(b) immediately preceding financial year.**

		As at <u>30-Jun-15</u>	As at <u>31-Mar-15</u>
		US cent	US cent
Net assets per ordinary share			
-Group		61.13	60.36
-Company		45.98	46.27
Number of shares in issue at end of period ('000)		<u>1,684,050</u>	<u>1,680,706</u>

Net assets per share is calculated by dividing the net assets by the number of ordinary shares in issue as at the balance sheet date.

**8. A review of the performance of the group, to the extent necessary for a reasonable understanding of the group's business. The review must include a discussion of the following:-**

- (a) any significant factors that affected the turnover, costs, and earnings of the group for the current financial period reported on, including (where applicable) seasonal or cyclical factors; and**  
**(b) any material factors that affected the cash flow, working capital, assets or liabilities of the group during the current financial period reported on.**

**Financial Review for the first quarter ended 30 June 2015**

**Overview:**

Consistent with the trend over the recent quarters, the Company demonstrated a meaningful improvement in its operating income in Q1 FY16. Excluding licensing revenue, operating income more than doubled compared to the same period last year, thanks to the execution of its cost reduction initiatives. In addition, product gross margin has also improved and operating cash flow remained strong. In regards to the top-line, lower licensing revenue and currency headwinds continued to weigh on the Company's results. On the pipeline front, the Company's LEADERS FREE clinical trial has completed all the follow-up studies according to plan and the findings will be presented at TCT later this year.

**Revenue:**

Total revenue, including licensing and royalty revenue, for the quarter decreased 16% to US\$67.0 million from US\$80.2 million in the previous year's corresponding quarter. Total product revenue for the quarter ended 30 June 2015 was US\$60.5 million, compared to US\$70.5 million recorded in the previous year's corresponding quarter. The cardiac diagnostic revenue fell to US\$3.3 million from US\$4.4 million in the same quarter of last year due to some installation delays by hospitals on the Company's D-SPECT products. Interventional Cardiology product revenue were US\$53.5 million compared to US\$61.7 million in the same quarter last year. Critical care product revenue also decreased to US\$3.8 million from the US\$4.4 million in the same quarter last year.

The table below shows the Group's revenue and the principal components of the revenue, as a percentage of total revenue, for the periods indicated:

<u>Revenue by business segments - 1st Quarter</u>	<u>Q1 FY 2016</u>	<u>%</u>	<u>Q1 FY 2015</u>	<u>%</u>
	<u>US\$'000</u>		<u>US\$'000</u>	
Critical care	3,756	6%	4,377	5%
Interventional cardiology	53,504	80%	61,695	78%
Cardiac diagnostic	3,272	4%	4,397	5%
Total product revenue	60,532	90%	70,469	88%
Licensing and royalties revenue	6,495	10%	9,742	12%
Total revenue	67,027	100%	80,211	100%

#### **Cost of sales and gross profit:**

Overall gross margin for products was 74% for the quarter ended 30 June 2015, compared to 71% for the previous year's corresponding quarter. This was attributable mainly to higher gross profit margins from the cardiac diagnostic business and higher interventional cardiology gross margin through a more vertical integrated production process.

The table below shows the Group's gross profit by business segments, as a percentage of segment revenue, for the periods indicated:

<u>Gross profit by business segments - 1st Quarter</u>	<u>Q1 FY 2016</u>	<u>Gross Margin</u>	<u>Q1 FY 2015</u>	<u>Gross Margin</u>
	<u>US\$'000</u>	<u>%</u>	<u>US\$'000</u>	<u>%</u>
Critical care	1,637	44%	1,907	44%
Interventional cardiology	40,493	76%	45,621	74%
Cardiac diagnostic	2,404	73%	2,461	56%
Total product gross profit	44,534	74%	49,989	71%
Licensing and royalties revenue	6,495	100%	9,742	100%
Total gross profit	51,029	76%	59,731	74%

#### **Operating expenses:**

The Group's total operating expenses for the first quarter were US\$32.7 million compared to US\$44.6 million for the first quarter in the previous year. Total operating expenses as a percentage of product revenue for the quarter was 54%, compared to 63% in the previous year same quarter.

(i) Sales and marketing expenses

Sales and marketing expenses decreased 25% to US\$20.3 million for the quarter ended 30 June 2015 compared to US\$26.9 million for the quarter ended 30 June 2014 mainly due to reduction in payroll related expenses, marketing and promotion expenses, warehousing & logistics expenses and doubtful debt expenses.

(ii) General and administrative expenses

General and administrative expenses were US\$7.8 million for the quarter ended 30 June 2015 compared to US\$10.7 million in the previous year's corresponding quarter, a decrease of 26%, mainly due to decreased payroll related expenses, share-based expenses, consulting and professional fees.

(iii) Research and development expenses

Research and development expenses decreased 34% to US\$4.6 million for the quarter ended 30 June 2015 compared to US\$7.0 million in the quarter ended 30 June 2014. The decrease was attributable mainly to lower payroll related expenses and clinical and animal trials expenses.

(iv) Other operating income/(expenses)

Other operating income for the quarter was mainly the exchange losses from the depreciation of SGD and EUR against USD during the period.

#### **Income tax**

Income tax for the current quarter ended 30 June 2015 includes mainly corporate income tax expenses.

#### **Net result after tax:**

The net result for the quarter ended 30 June 2015 was a net profit after tax of US\$9.5 million as compared to a net profit after tax of US\$9.9 million for the same quarter in the previous year. The decrease in net result for the quarter as compared to the prior year's corresponding period was attributable mainly to decrease in revenue.

#### **Use of proceeds from the issue of 4.875% fixed rate notes due 2017**

The Company refers to its announcement on 23 January 2013 in relation to the issuance of an aggregate of S\$300 million (approximate US\$222 million) in principal amount of 4-year notes with interest at a rate of 4.875%, payable semi-annually in arrear.

As at 30 June 2015, out of the total net proceeds of S\$295.4 million (approximate US\$218.8 million) from the issuance of 4-year notes, the Company paid US\$84.7 million for the acquisition of the business of Spectrum Dynamics, technical know-how of DES and other unquoted investments.

The Company will continue to make periodic announcements on the utilisation of the proceeds from the notes issue as and when such proceeds are materially deployed.

**9. Where a forecast, or a prospect statement, has been previously disclosed to shareholders, any variance between it and the actual results.**

Not Applicable.

**10. A commentary at the date of the announcement of the significant trends and competitive conditions of the industry in which the group operates and any known factors or events that may affect the group in the next reporting period and the next 12 months.**

The Company maintains its outlook for the fiscal year ending 31 March 2016 ("FY16") provided during its last earning release for Q4 FY15. Management still aims to continue to work towards revenue growth over FY15 although it continues to expect market competition, pricing pressure, and unfavourable currency impact to stay as headwinds. In addition, licensing income from partner, Terumo, could continue to decrease. The revenue growth is expected to be largely driven by sales from BioFreedom™ and the Cardiac Diagnostic segment as well as further expansion in Japan and emerging markets.

Looking ahead, the Company still targets to achieve revenue growth for this fiscal year, as the Company had anticipated a slow start for FY16 under the backdrops of lower licensing and royalty revenue and adverse foreign exchange impact. In regards to operating income growth, the better performance in the past three quarters demonstrated that the Company is heading in the right direction and it will continue to work towards improving its operational efficiency and productivity.

Longer term, the Company's strategies remain sound – it will continue to enhance its competitiveness and increase its market share in the global cardiovascular markets, while also seeking new growth businesses and other attractive opportunities. The management is confident that they are on the right track to further grow Biosensors to become a bigger, more diversified and more profitable international organization in the medical device field.

**11. Dividend**

**(a) Current Financial Period Reported On**

Any dividend declared for the current financial period reported on? None

**(b) Corresponding Period of the Immediately Preceding Financial Year**

Any dividend declared for the corresponding period of the immediately preceding financial year? None

**(c) Date payable**

Not applicable.

**(d) Books closure date**

Not applicable.

**12. If no dividend has been declared/recommendeded, a statement to that effect.**

No dividend has been declared or recommended during the period under review.

**13. Interested person transactions**

There were no new interested person transactions during the first quarter ended 30 June 2015 under Chapter 9 of the Listing Manual.

**BY ORDER OF THE BOARD**

**Yoh-Chie Lu**  
**Chairman**  
**3 August 2015**



**Statement by Directors**  
**Pursuant to SGX Listing Rule 705(4)**

In the opinion of management, the accompanying unaudited consolidated interim financial statements have been prepared on a consistent basis with the March 31, 2015 audited consolidated financial statements. The unaudited consolidated financial statements are presented in accordance with International Financial Reporting Standards ("IFRS"). The preparation of consolidated financial statements in conformity with IFRS requires management to make estimates and assumptions that affect the amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and reported amounts of revenues and expenses during the reporting periods, and therefore the actual results may differ from those estimates. The consolidated interim financial statements should be read in conjunction with the consolidated financial statements and accompanying notes thereto included in our FY 2014/15 annual report.

To the best of our knowledge, nothing has come to the attention of the Directors which may render the interim financial results to be false or misleading. Based on our knowledge, the financial statements and other financial information included in this report, present fairly in all material respects the financial conditions, results of operations and cash flows of the Group as of, and for, the periods presented in this announcement.

**On Behalf of the Board**

**Yoh-Chie Lu**  
**Chairman**

**Jose Calle Gordo**  
**CEO**

**3 August 2015**

**BIOSENSORS INTERNATIONAL GROUP, LTD.**

Registered Address : Clarendon House, 2 Church Street, Hamilton HM 11, Bermuda

Mailing Address : 36 Jalan Tukang, Singapore 619266

[www.biosensors.com](http://www.biosensors.com)